TriLink BioTechnologies today announced it opened its new cGMP mRNA manufacturing facility. The new 32,000 sq. ft. facility, based in San Diego, is specifically designed for mRNA manufacturing. Using the company’s mRNA manufacturing capabilities, it will support late-phase drug developers from Phase 2 to commercialization. TriLink said the opening is expected to help advance the…
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
Sen-Jam Pharmaceutical this week announced it is partnering with specialty pharmaceutical manufacturer KVK-Tech for formulation and chemistry, manufacturing and controls for anti-inflammatory injectables. The partnership is the third development, manufacturing, distribution and license agreement the pair have signed. The new partnership will further advance Sen-Jam’s first injectable anti-inflammatory therapeutic, SJP-100. Sen-Jam is developing an immunomodulator…
Gilead, Xilio sign license agreement for Xilio tumor-activated immuno-oncology therapy
Gilead and Xilio recently announced an exclusive license agreement to develop and commercialize Xilio’s XTX301, a Phase 1 tumor-activated IL-12 program. Waltham, Massachusetts-based Xilio Therapeutics is a clinical-stage biotechnology company that is developing tumor-activated immuno-oncology therapies. It is using a tumor-activated platform to build tumor-activated molecules, including antibodies, cytokines, bispecifics and cell engagers. Each of…
Cardinal Health starts construction on new pharmaceutical distribution center
Cardinal Health (NYSE:CAH) this week announced it began construction on its new pharmaceutical distribution center in Columbus, Ohio. The new 350,000 sq ft. logistics center will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products to support the company’s pharmaceutical business. Dublin, Ohio-based Cardinal Health’s Consumer Health Logistics Center will…
Catalent cuts 300 jobs ahead of acquisition by Novo Holdings
Catalent said this week that it reduced its headcount by approximately 300 employees as part of a restructuring effort. The company confirmed the workforce reduction in its 10-Q quarterly report, filed on Feb. 14. This also coincides with preparations for an acquisition as Novo Holdings agreed to buy the leading pharmaceutical CDMO for $16.5 billion…
Report: Pharma kicks off year with drug price hikes
Reuters reports that a number of big-name drugmakers, including Pfizer, Sanofi and Takeda plan to raise drug prices to start the year. According to the report, the price hikes apply to more than 500 drugs. Excluding different doses and formulations, the reach extends to more than 140 brands of drugs. Reuters said healthcare research firm 3…
Commitment to operational efficiency and partnerships yield dividends for Teva
Teva’s strategy to boost its operational efficiency and tap strategic partnerships seems to be paying off. In its Q3 earnings report, Teva announced that global revenues were up to $3.9 billion, marking a 7% rise from the previous year’s third quarter. Factors fueling the growth include the robust performance of their specialty medications, Austedo and…
Transparency-Rx promises reform in the PBM landscape
Pharmacy benefit managers (PBMs) have recently emerged as a punching bag with the pharma trade group PhRMA accusing such orgs of driving up drug prices. Now, an alliance of PBMs known as Transparency-Rx has emerged, promising a reform initiative in a digital campaign attempting to put pressure on rival PBMs. This coalition’s efforts could reshape…
Survey: Cybersecurity is top concern of pharma C-suites
Cybersecurity is a concern for two-thirds of pharmaceutical C-suites (66%), according to a recent survey from Rackspace and Microsoft. The priority came ahead of supply chain/logistics management (55%) and sustainability (53%). See full data below: Data breaches in the pharma sector are costly, with the average cost of remediation topping $10 million in 2022, according…
PBMs increasingly under fire in drug-pricing battle
As the national debate over drug pricing ramps up, Pharmacy Benefit Managers (PBMs) find themselves squarely in the spotlight. PhRMA, which has also criticized hospitals for marking up drug prices by as much as 500%, launched a seven-figure ad campaign targeting proposals in Congress to lower drug prices. PhRMA, which counts companies such as Pfizer,…